Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland

Lehtinen, Matti; Apter, Dan; Eriksson, Tiina; Harjula, Katja; Hokkanen, Mari; Natunen, Kari; Nieminen, Pekka; Paavonen, Jorma; Palmroth, Johanna; Petäjä, Tiina; Pukkala, Eero; Vänskä, Simopekka; Cheuvart, Brigitte; Soila, Maaria; Bi, Dingren; Struyf, Frank

doi:10.1002/cam4.4299

Cited by 3 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study consists of 753 HPV16/18 vaccinated women who originally participated in the community-based Finnish HPV vaccination trial as previously described [ 22 ]. Bivalent HPV vaccine was given to the participants at the age of 13–15.…”

Section: Methodsmentioning

confidence: 99%

The quality of life of frequently vs. infrequently screened HPV vaccinated women

Taavela,

Eriksson,

Huhtala

et al. 2024

Qual Life Res

Self Cite

View full text Add to dashboard Cite

Purpose Cervical lesions caused by human papillomavirus (HPV) are related to decreased quality of life (QoL) of women. Also, cervical cancer (CC) screening can cause psychological adverse effects. It has been assumed that by decreasing the HPV-related disease burden, HPV vaccinations would increase the QoL. This study compares the effect of CC screening on QoL of HPV vaccinated women in two different screening protocols. Methods A total of 753 HPV16/18 vaccinated women were randomized to frequent (22/25/28 years of age) and infrequent (28 years of age) CC screening arms. QoL questionnaires (EQ VAS, RAND 36, amended CECA 10) were sent at the age of 28. Results Median EQ VAS scores were 80 (Q1–Q3 75–90) in both screening arms. Mean RAND 36 scores of frequently and infrequently screened women were 78.13/81.64 in Physical role functioning domain and, respectively, 77.93/80.18 in Pain, 69.10/69.12 in General Health, 54.67/53.61 in Energy, 83.72/85.11 in Social functioning, 69.53/69.68 in Emotional role functioning, and 68.16/69.29 in Emotional well-being domain. Among women with a self-reported history of Pap cytology abnormalities, overall mean scores of amended CECA 10 were 69.52/72.07, and among women with a self-reported history of genital warts, 60.09/66.73, respectively. Conclusion There was no significant difference in the QoL of HPV vaccinated women between the two CC screening arms. Women were mostly satisfied with the screening experience despite the screening frequency. This information is important for the future screening program planning as we need to reach the best possible balance with screening benefits and harms. Trial registration number NCT02149030, date of registration 29/5/2014.

show abstract

Section: Methodsmentioning

confidence: 99%

The quality of life of frequently vs. infrequently screened HPV vaccinated women

Taavela,

Eriksson,

Huhtala

et al. 2024

Qual Life Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…A eficácia contra CIN3+ associada ao HPV-16 e/ou -18 foi de 34% em todas as idades, mas não foi significativa. VE uniforme e estatisticamente significativa contra NIC1+, NIC2+ e NIC3+ associados a HPV-16/18 foi observada apenas no estrato de 15 a 17 anos (74%, 73% e 75%, respectivamente).Brazilian Journal of Development, Curitiba, v.9, n.7, p. 22330-22341, jul., 2023 infecções e lesões precursoras de câncer cervical (>95%, injeção antes da exposição ao HPV) de qualquer grau relacionado aos tipos de HPV cobertos pela vacina[15,43,44]. Ela também mostrou cerca de 90% e Brazilian Journal of Development, Curitiba, v.9, n.7, p. 22330-22341, jul., 2023 [19-23]) e 139 receptores de uma dose do estudo IARC Índia (idade média de 14 anos [13-16]) foram incluídos na análise.…”

unclassified

A eficácia das vacinas disponíveis contra o HPV: uma revisão de literatura

Oliveira,

Coelho,

Saud

et al. 2023

Braz. J. Develop.

View full text Add to dashboard Cite

O câncer de colo uterino (CCU) é um dos tumores mais frequentes na população feminina, sendo o terceiro mais comum e a quarta causa de morte por câncer em mulheres. O vírus que está relacionado ao CCU é o papiloma vírus humano (HPV), sendo que os tipos 16 e 18 estão presentes em 70% dos casos de câncer do colo do útero. Diante disso, este trabalho tem por objetivo revisar a eficácia das vacinas disponíveis atualmente contra o HPV. Nesse sentido, para a pesquisa, utilizou-se as bases de dados eletrônicas PubMed/MEDLINE e Scielo, os artigos que continham a temática buscada, originais indexados e com embasamento científico foram selecionados, utilizando-se 16 artigos entre os anos de 2005 a 2023. Até o momento, 3 vacinas contra o HPV são aprovadas pelo FDA (Food and Drug Administration), a quadrivalente, a bivalente e a nonavalente. Com o presente estudo, observou-se que a eficácia de todas é alta, principalmente contra os tipos 16 e 18 e são seguras, constatou-se efeitos colaterais mínimos, apresentando benefícios superiores aos riscos. Diante do exposto, é de suma importância que a vacinação seja aderida pela população, para que ocorra menos casos de câncer de colo uterino.

show abstract